Cutaneous Adverse Reactions of Amiodarone

Krzysztof Jaworski
Irena Walecka
Lidia Rudnicka
Maciej Gnatowski
Dariusz A. Kosior

Corresponding Author:
Dariusz A. Kosior, e-mail: dkosior@imdik.pan.pl

Source of support:
Self financing

1 Department of Cardiology and Hypertension, Central Clinical Hospital of the Ministry of Interior, Warsaw, Poland,
2 Department of Dermatology, Central Clinical Hospital of the Ministry of Interior, Warsaw, Poland,
3 Department of Dermatology, Medical University of Warsaw, Warsaw, Poland
4 Department of Traumaorthopedic Surgery, District Hospital, Wolomin, Poland
5 Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland

Dermatological complications of amiodarone are commonly encountered problems in therapy. The incidence in the population of patients with prolonged use of amiodarone reaches nearly 75% according to various sources. Nevertheless, they are often misdiagnosed or overlooked. The aim of this review is to present the current state of knowledge about skin changes induced by amiodarone, including phototoxic and photoallergic reactions, as well as hyperpigmentation. In most cases, the adverse effects are reversible and disappear after discontinuation of the drug. Although the dermatological complications usually do not influence the outcome of the therapy and rarely cause discontinuation of treatment, they have a great impact on patient quality of life.

MeSH Keywords:
Amiodarone • Dermatology • Phototoxic Reactions, Hyperpigmentation

Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/890881
Background

Dermatology and cardiology at a first glance seem to be very distinct medical fields, but the relationship between them is shown by the adverse effects of amiodarone, the key antiarrhythmic drug. Amiodarone has been used by physicians for over 50 years to treat supraventricular and ventricular cardiac arrhythmias, and it often provides the last treatment option due to its high efficacy. However, prolonged amiodarone therapy unfortunately carries an extended risk of adverse effects, mainly involving the thyroid gland, liver, lungs, eyes, and skin [1].

Dermatological complications of amiodarone are commonly encountered. The incidence in the population of patients with prolonged use of this drug reaches nearly 75% according to various sources. The main skin changes induced by amiodarone are phototoxic and photoallergic reactions, as well as hyperpigmentation. In most cases the adverse effects are reversible and disappear after drug withdrawal. Although the dermatological complications usually do not influence the outcome of the therapy and rarely cause the discontinuation of treatment, they have great impact on patient quality of life.

Phototoxic and Photoallergic Reactions

Phototoxic reactions are the most common dermatological adverse effect of amiodarone therapy, affecting 25–75% of patients on long-term treatment [2]. Photoallergy is considerably less likely to occur, but the risk also increases with prolongation of the therapy.

Amiodarone and its active metabolite, desethylamiodarone, cause decrease of MED (minimal erythema dose) in the range of ultraviolet radiation type A (UV-A 320–400 nm), which can reach up to 50% of the correct values. In individual cases there may also be a reduction of MED for the ultraviolet type B radiation (UV-B 290–320 nm) [3]. The mechanism of the reaction seems to be connected with the creation of active metabolites due to radiation, such as oxygen free radicals, which in turn leads to destruction of DNA particles, cell membranes, and oxygenation of lipids [4,5]. Ferguson et al. demonstrated phototoxic effects of amiodarone and desethylamiodarone by carrying out in vitro tests with the use of photohemolysis, DNA synthesis inhibition assay in PHA-stimulated lymphocytes, and the killing of macrophages obtained from mouse peritoneal fluid [6].

Skin changes usually occur after at least 4 months of therapy and with the minimal cumulative dose, which is 40 g [7]. They have the typical erythematous or eczematous appearance with accompanying pruritus in the parts exposed to sunlight, usually on the hands, face, and neck. The eruptions are less prominent on the chin, lower lip, and behind the ears [8]. The symptoms begin several minutes after exposure to the sunlight, continue up to 24 hours and usually subside by around 48 hours, but in some cases they persist up to 72 hours. Phototoxic and photoallergic reactions might even occur a few months after the withdrawal of amiodarone due to its long elimination time, which on average takes 35–40 days, and in obese patients can take 100 days for complete excretion. In the literature there are also descriptions of prolonged photosensitivity cases (up to 15 years following the discontinuation of therapy) [9]. The extent of the reactions depends mostly on the individual sensitivity of the skin to sunlight, but it is always proportional to the exposure time.

The basis of therapy is withdrawal of the medication and restoration of skin lipid layers. It also includes the use of medium strength topical glucocorticoid, oral non-steroidal anti-inflammatory drugs, and intensive sunscreen protection [8].

Prevention of acute reactions caused by sunlight in patients treated with amiodarone should include avoidance of frequent sun exposure on the skin and the proper application of external sun protection products with high protection factors (SPF 50 or 50+), reapplied not less frequently than approximately every 2 hours. Sunscreen should provide the full spectrum of protection, including a UV-A radiation. Particularly effective are creams containing zinc oxide or titanium dioxide [10]. Glass commonly used in windows is permeable to UV-A radiation and does not provide protection to people in buildings and cars.

Hyperpigmentation

Skin hyperpigmentation is another important adverse effect, affecting 4–9% of patients taking amiodarone [2]. In contrast to the phototoxic reactions, which do not depend on the skin type, hyperpigmentation usually occurs in patients with skin type I phototype [7]. In these patients, long-term therapy with amiodarone leads to characteristic blue-grey discolourations, located mostly on the face, ears, and palms of the hands (Figure 1). The mechanism by which these changes occur is not precisely understood. Histopathological examination of the skin shows yellow-brown deposits of lipofuscin aggregates within macrophages, mast cells, endothelial cells, smooth muscle cells, keratinocytes, and fibroblasts [11]. Pathologically accumulated phospholipids appear under electron microscopy as irregular or oval structures. Some authors report that the hyperpigmentation is likely due to the amiodarone deposits instead of lipofuscin [12,13]. Amiodarone binds to phospholipids and creates insoluble compounds that do not follow the regular degradation pathways, which leads to their accumulation in cellular lysosomes. The discovery of increased amounts of iodine or drug metabolites in granules proves that
are accounts of very successful therapy with UV-B rays, leading to higher tolerance to sunlight and prolongation of possible exposure times without adverse effects [18].

**Pseudoporphyria**

Amiodarone is considered to be a cause of pseudoporphyria, which is a disease with clinical picture similar to this of porphyria cutanea tarda, but without any identified biochemical changes in the metabolism of porphyrins. Pseudoporphyria is usually manifested by tense bullae, erosions, scars, postinflammatory hyperpigmentation, and increased skin fragility, especially in the sun-exposed regions.

**Linear IgA Bullous Dermatosis**

A very rare adverse reaction to amiodarone treatment is linear IgA bullous dermatosis, and it is thought that amiodarone can exacerbate the course of this disease. Characteristic changes include the presence of well-differentiated blisters located either on healthy skin or on erythematous and edematous areas. Location of the changes does not correspond to the sun-exposed parts of the skin.

**Effects of Amiodarone Therapy on Other Cutaneous Diseases**

The amiodarone molecule contains a large amount of inorganic iodine, which may exacerbate certain skin diseases, such as dermatitis herpetiformis and psoriasis. Moreover, there have been reports of post-amiodarone pseudo-purulent changes, such as acne or blister-purulent lesions characteristic of iodism [19,20]. This should be considered when choosing the optimal antiarrhythmic therapy.

**Other Adverse Effects**

Less common dermatological complications of amiodarone include hives, pruritus, erythema nodosum, purpura, and the most severe variant of erythema multiforme – toxic epidermal necrolysis [21,22]. The acute complication of treatment with intravenous amiodarone administration can take on the form of necrosis of the skin and soft tissue due to venous extravasation. The risk is related to low pH (3.5–4.5) of the solution and the content of solvents, such as benzyl alcohol and polysorbates [23].

There are some reports indicating the possible carcinogenic effects of amiodarone. A few cases of basal cell carcinoma associated with chronic use of this drug have been reported.
Most of the changes were observed on the site of a preexisting acute phototoxic reaction [24,25].

Conclusions

Complications of chronic amiodarone therapy compel the prescribing physician to inform the patient about all possible adverse reactions, methods of avoiding them, and the need for specialist advice if symptoms occur. Any doctor approached by a patient with skin lesions secondary to amiodarone must be aware of the risks of stopping treatment, because it can exacerbate the severity of arrhythmias and even lead to sudden cardiac death. Cooperation between cardiologists and dermatologists will undoubtedly facilitate risk stratification and ensure that optimal decisions will be made to provide maximum safety of the patient, while at the same time reducing the adverse effects.

References:

1. Punnam SR, Goyal SK, Kotaru VP et al: Amiodarone – a ‘broad spectrum’ antiarrhythmic drug. Cardiovasc Hematol Disord Drug Targets, 2010; 10(1): 73–81
2. Vassallo P, Trohman RG: Prescribing amiodarone: an evidence-based review of clinical indications. JAMA, 2007; 298(11): 1312–22
3. Zachary CB, Slater DN, Holt DW et al: The pathogenesis of amiodarone-induced pigmentation and photosensitivity. Br J Dermatol, 1984; 110(4): 451–56
4. Reid L, Khamno N, Clothier RH: An evaluation of the effects of photovitiation of bithionol, amiodarone and chlorpromazine on human keratinocytes in vitro. Altern Lab Anim, 2007; 35(5): 471–85
5. Waltera S, Butany J, From L et al: Cutaneous ultrastructural changes and photosensitivity associated with amiodarone therapy. J Am Acad Dermatol, 1987; 16: 779–87
6. Ferguson J, Addo HA, Jones S et al: A study of cutaneous photosensitivity induced by amiodarone. Br J Dermatol, 1985; 113: 537–49
7. Rappersberger K, Honigsmann H, Ortel B et al: Photosensitivity and hyperpigmentation in amiodarone-treated patients: incidence, time course, and recovery. J Invest Dermatol, 1989; 93: 201–9
8. Drucker AM, Rosen CF: Drug-induced photosensitivity: culprit drugs, management and prevention. Drug Saf, 2011; 34(10): 821–37
9. Yones SS, O’Donoghue NB, Palmer RA et al: Persistent severe amiodarone-induced photosensitivity. Clin Exp Dermatol. 2005;30(5): 500–2.
10. McKenna WI, Rowland E, Krikler DM: Amiodarone: the experience of the past decade. Br Med J (Clin Res Ed), 1983; 287(6406): 1395
11. Miller RA, McDonald AT: Dermal Lipofuscinosis associated with amiodarone therapy. Arch Dermatol, 1984; 120: 646–49
12. Ammoury A, Michaud S, Paul C et al: Photodistribution of blue-gray hyperpigmentation after amiodarone treatment: molecular characterization of amiodarone in the skin. Arch Dermatol, 2008; 144(1): 92–96
13. Trimble JW, Mendelson DS, Fetter BF et al: Cutaneous pigmentation secondary to amiodarone therapy. Arch Dermatol, 1983; 119: 914–18
14. Deree R: Drug-induced skin pigmentation. Epidemiology, diagnosis and treatment. Am J Clin Dermatol, 2001; 2(4): 253–62
15. Bernstein E: Q-switched laser treatment of amiodarone pigmentation. J Drugs Dermatol, 2011; 10(11): 1316–19
16. Karrer S, Hohenleutner U, Szeimies R, Landthaler M: Amiodarone-induced pigmentation resolves after treatment with the Q-switched ruby laser. Arch Dermatol, 1999; 135(3): 251–53
17. Wiper A, Roberts DH, Schmitt M: Amiodarone-induced skin pigmentation: Q-switched laser therapy, an effective treatment option. Heart, 2007; 93(3): 15
18. Collins P, Ferguson J: Narrow-band UVB (TL-01) phototherapy: an effective preventative treatment for the photodermatoses. Br J Dermatol, 1995; 132(6): 956–63
19. Jaworski K. et al.: Choroby skóry i choroby przenoszone drogą płciową, 1st ed., PZWL, 2008 [in Polish]
20. Abel EA, DiCicco LM, Orenberg EK et al: Drugs in exacerbation of psoriasis. J Am Acad Dermatol, 1986; 15: 1007–22
21. Bencini PL, Crosti C, Sala F et al: Toxic epidermal necrolysis and amiodarone treatment. Arch Dermatol, 1985; 121(7): 838
22. Yung A, Agnew K, Snow J, Oliver F: Two unusual cases of toxic epidermal necrolysis. Australas J Dermatol, 2002; 43(1): 35–38
23. Russell SJ, Saltissi S: Amiodarone induced skin necrosis. Heart, 2006; 92(10): 1395
24. Monk BE: Basal cell carcinoma following amiodarone therapy. Br J Dermatol, 1995; 133(3): 148–49
25. Maoz KB, Dvash S, Brenner S, Brenner S: Amiodarone-induced skin pigmentation and multiple basal-cell carcinomas. Int J Dermatol, 2009; 48(12): 1398–400

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License